Pfizer After Lipitor Slims Down to Push Mini-Blockbusters

Pfizer Inc.’s long dependence on the cholesterol pill Lipitor to produce almost one-fifth of the company’s revenue begins eroding today when the drug’s patent protection ends in the U.S.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.